Modification of imidazothiazole derivatives gives promising activity in B-Raf kinase enzyme inhibition; synthesis, in vitro studies and molecular docking
(2020)
Journal Article
Ammar, U. M., Abdel-Maksoud, M. S., Mersal, K. I., Ali, E. M., Yoo, K. H., Choi, H. S., Lee, J. K., Cha, S. Y., & Oh, C. (2020). Modification of imidazothiazole derivatives gives promising activity in B-Raf kinase enzyme inhibition; synthesis, in vitro studies and molecular docking. Bioorganic and Medicinal Chemistry Letters, 30(20), Article 127478. https://doi.org/10.1016/j.bmcl.2020.127478
B-Raf mutation was identified as a key target in cancer treatment. Based on structural features of dabrafenib (potent FDA approved B-Raf inhibitor), the design of new NH2-based imidazothiazole derivatives was carried out affording new highly potent d... Read More about Modification of imidazothiazole derivatives gives promising activity in B-Raf kinase enzyme inhibition; synthesis, in vitro studies and molecular docking.